ChemoCentryx (NASDAQ:CCXI) and GTX (NASDAQ:GTXI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability and dividends.

Risk & Volatility

ChemoCentryx has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500. Comparatively, GTX has a beta of 2.14, meaning that its share price is 114% more volatile than the S&P 500.

Insider & Institutional Ownership

53.8% of ChemoCentryx shares are held by institutional investors. Comparatively, 12.3% of GTX shares are held by institutional investors. 14.5% of ChemoCentryx shares are held by company insiders. Comparatively, 40.9% of GTX shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for ChemoCentryx and GTX, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ChemoCentryx 0 3 2 1 2.67
GTX 0 2 0 0 2.00

ChemoCentryx presently has a consensus price target of $17.10, suggesting a potential upside of 38.01%. GTX has a consensus price target of $31.00, suggesting a potential upside of 3,128.49%. Given GTX’s higher probable upside, analysts plainly believe GTX is more favorable than ChemoCentryx.

Profitability

This table compares ChemoCentryx and GTX’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ChemoCentryx 13.88% 32.16% 6.49%
GTX N/A -126.41% -100.34%

Valuation and Earnings

This table compares ChemoCentryx and GTX’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ChemoCentryx $82.50 million 7.59 $18.19 million $0.36 34.42
GTX N/A N/A -$30.43 million ($1.75) -0.55

ChemoCentryx has higher revenue and earnings than GTX. GTX is trading at a lower price-to-earnings ratio than ChemoCentryx, indicating that it is currently the more affordable of the two stocks.

Summary

ChemoCentryx beats GTX on 11 of the 14 factors compared between the two stocks.

ChemoCentryx Company Profile

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). The company is also developing Avacopan for the treatment of patients with C3 glomerulopathy (C3G), hidradenitis suppurativa (HS), and in atypical hemolytic uremic syndrome (aHUS). In addition, the company is developing CCX140, an inhibitor of the chemokine receptor known as CCR2, which has completed a Phase II clinical trial in diabetic nephropathy (DN) and is being developed for patients with focal segmental glomerulosclerosis (FSGS). Further, it has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases, and in cancer. The company was founded in 1997 and is headquartered in Mountain View, California.

GTX Company Profile

GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for the treatment of stress urinary incontinence (SUI) and prostate cancer. It focuses on the development of selective androgen receptor modulators (SARMs) for the treatment of breast cancer, SUI, and Duchenne muscular dystrophy; and selective androgen receptor degraders to treat progressive castration-resistant prostate cancer. The company's lead SARM candidate is the enobosarm GTx-024, a Phase II open-label proof-of-concept clinical trial for patients with androgen receptor (AR) positive triple-negative breast cancer; and estrogen receptor positive and AR positive advanced breast cancer, as well as postmenopausal women with SUI. GTx, Inc. was founded in 1997 and is headquartered in Memphis, Tennessee.

Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.